Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience
Chemoradiotherapy (ChT-RT) followed by 12-month durvalumab is the new standard treatment for unresectable stage III non-small cell lung cancer. Survival data for patients from everyday routine clinical practice is scarce, as well as potential impact on treatment efficacy of sequential or concomitant...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Sciendo
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/ae2e857754654969af9f34a239d8657f |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|